MedPath

Effect of erythropoiesis-stimulating agents on the progression of chronic kidney disease: a retrospective study

Not Applicable
Conditions
Chronic kidney disease patients with renal anemia
Registration Number
JPRN-UMIN000013311
Lead Sponsor
Department of Integrated Therapy for Chronic Kidney Disease, Graduate School of Medical Sciences, Kyushu University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with apparent hemorrhagic lesion 2. Patients with hematologic disease (e.g. leukemia, malignant lymphoma, myelodysplastic syndrome, aplastic anemia) 3. Patients with apparent chronic inflammation (e.g. rheumatoid arthritis, inflammatory bowel disease) 4. Patients with complication of malignant tumor

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in the deterioration rate of estimated glomerular filtration rate (eGFR) after administration of ESA
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath